白血球除去市場 : 2027 年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年10月

白血球除去市場 :製品(デバイス、フィルター、メンブレンセパレーター)、ロイコパック(動員、非動員)、適応症(ALL、NHL、多発性骨髄腫)、用途(研究、治療)、エンドユーザー(病院、製薬、バイオテクノロジー) – 2027 年までの世界予測
Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) – Global Forecast to 2027

ページ数 285
図表数 303
種別 英文調査報告書
価格

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

The global leukapheresis market is projected to reach USD 98 Million by 2027 from USD 65 Million in 2022, at a CAGR of 8.5%. The global leukopaks market is projected to reach USD 784 Million by 2027 from USD 146 Million in 2022, at a CAGR of 39.8%. Due to the cases of leukemia rising globally, and rising need for leukopaks in clinical trials and other research applications, the leukapheresis market is expected to grow in the forecast period.

Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2027
“By application, the research applications was the larger segment in the leukapheresis products market in 2021.”
By, application, the leukpaheresis market is segmented into research applications and therapeutic applications. The research applications segment accounted for the larger share of the leukapheresis products market in 2021. The growing development of cell-based immunotherapies and rising demand for leukapheresis-derived primary cells in drug development are some of the major factors driving the growth of the leukapheresis products market during the forecast period.

製品(デバイス、フィルター、メンブレンセパレーター)、ロイコパック(動員、非動員)、適応症(ALL、NHL、多発性骨髄腫)、用途(研究、治療)、エンドユーザー(病院、製薬、バイオテクノロジー
“Among end users, the academic & research institutes segment accounted for the largest share of the leukopaks market in 2021.”
By end user, the leukopaks market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2021, the academic & research institutes segment accounted for the largest share of the leukapheresis products market. The increasing number of industry-academic partnerships for conducting research on cell-based cancer therapies are driving the growth of this end-user segment.
“In 2021, North America accounted for the largest regional market for leukopaks market“
This can be attributed to the presence of a large number of leukopak manufacturing companies in the region, and easy accessibility to technologically advanced blood separation devices, among other factors. The Asia Pacific region is expected to be the fastest growing region in the forecast period. The increasing CAR-T cell therapy research and rising number of pharma & biotech companies and research institutes in China are some of the factors driving market growth.

A breakdown of the primary participants referred to for the leukapheresis market is provided below:
• By Company Type (Supply-side): Tier 1: 35%, Tier 2: 30%, and Tier 3: 35%
• By Designation: C-level: 30%, Director-level: 30%, and Others: 40%
• By Region: North America: 45%, Europe: 25%, Asia-Pacific: 20%, and Rest of the World: 10%
Prominent players in the leukapheresis market include Asahi Kasei Corporation (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), and Miltenyi Biotec (Germany).
Some prominent players in the leukopaks market are Discovery Life Sciences (US), StemExpress, LLC (US), Charles River Laboratories International, Inc. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), and ZenBio (US).

Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2027
Research Coverage:
The report analyzes the leukapheresis market and aims at estimating the market size and future growth potential of this market based on various segments such as product, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the leukapheresis market. The report analyzes two sub-markets– Leukpaheresis products market and leukopaks market, based on the product type, application/indication, end user, and region.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the leukapheresis products and leukopaks market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of leukapheresis products and leukopaks across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the leukapheresis products and leukopaks market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the leukapheresis products and leukopaks markets.


目次

1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 36
1.2.1 INCLUSIONS AND EXCLUSIONS 36
1.3 MARKET SCOPE 37
1.3.1 MARKETS COVERED 37
1.3.2 YEARS CONSIDERED 38
1.4 CURRENCY CONSIDERED 38
TABLE 1 STANDARD CURRENCY CONVERSION RATES 38
1.5 STAKEHOLDERS 38
1.6 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 1 RESEARCH DESIGN 41
2.1.1 SECONDARY DATA 42
2.1.1.1 Key data from secondary sources 43
2.1.2 PRIMARY DATA 44
FIGURE 2 PRIMARY SOURCES 44
2.1.2.1 Key data from primary sources 45
2.1.2.2 Insights from primary experts 46
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS (LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET) 46
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION (LEUKAPHERESIS PRODUCTS MARKET) 47
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (LEUKOPAKS MARKET) 47
2.2 MARKET SIZE ESTIMATION: LEUKAPHERESIS MARKET 48
FIGURE 6 SUPPLY SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 48
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION 49
FIGURE 8 REVENUE ANALYSIS OF THE TOP 4 COMPANIES: LEUKAPHERESIS MARKET (2020) 49
FIGURE 9 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET) 51
FIGURE 10 TOP-DOWN APPROACH 51
2.3 MARKET SIZE ESTIMATION: LEUKOPAKS MARKET 52
FIGURE 11 VOLUME ESTIMATION OF LEUKOPAKS MARKET 53
FIGURE 12 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS (LEUKOPAKS MARKET) 54
FIGURE 13 TOP-DOWN APPROACH 54
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 55
FIGURE 14 MARKET DATA TRIANGULATION METHODOLOGY 55
2.5 MARKET SHARE ANALYSIS 56
2.6 RESEARCH ASSUMPTIONS 56
2.7 LIMITATIONS 56
2.7.1 METHODOLOGY-RELATED LIMITATIONS 56
2.7.2 SCOPE-RELATED LIMITATIONS 56
2.8 RISK ASSESSMENT 57
TABLE 2 RISK ASSESSMENT: LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKET 57
3 EXECUTIVE SUMMARY 58
FIGURE 15 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 58
FIGURE 16 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 59
FIGURE 17 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 59
FIGURE 18 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 60
FIGURE 19 LEUKOPAKS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 61
FIGURE 20 LEUKOPAKS MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION) 61
FIGURE 21 LEUKOPAKS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 62
FIGURE 22 GEOGRAPHIC SNAPSHOT: LEUKAPHERESIS PRODUCTS MARKET 63
FIGURE 23 GEOGRAPHIC SNAPSHOT: LEUKOPAKS MARKET 64
4 PREMIUM INSIGHTS 65
4.1 LEUKAPHERESIS PRODUCTS MARKET: OVERVIEW 65
FIGURE 24 INCREASING INCIDENCE AND PREVALENCE OF LEUKEMIA TO DRIVE MARKET 65
4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY 65
FIGURE 25 LEUKAPHERESIS DISPOSABLES TO DOMINATE NORTH AMERICAN LEUKAPHERESIS PRODUCTS MARKET IN 2021 65
4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX 66
FIGURE 26 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 66
4.4 LEUKAPHERESIS PRODUCTS MARKET: REGIONAL MIX 66
FIGURE 27 NORTH AMERICA DOMINATED MARKET IN 2021 66
4.5 LEUKOPAKS MARKET: OVERVIEW 67
FIGURE 28 FAVORABLE GOVERNMENT SUPPORT AND RISING DEMAND FOR LEUKOPAKS IN RESEARCH APPLICATIONS TO DRIVE MARKET 67
4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY 68
FIGURE 29 MOBILIZED LEUKOPAKS COMMANDED LARGEST SHARE OF MARKET IN 2021 68
4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX 69
FIGURE 30 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 69
4.8 LEUKOPAKS MARKET: REGIONAL MIX 69
FIGURE 31 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 32 LEUKAPHERESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70
5.2.1 DRIVERS 71
5.2.1.1 Rising incidence and prevalence of leukemia 71
FIGURE 33 ESTIMATED NUMBER OF NEW CASES OF LEUKEMIA, BY REGION (2020-2040) 71
FIGURE 34 ESTIMATED NUMBER OF LEUKEMIA DEATHS, BY REGION (2020-2040) 72
5.2.1.2 Increasing number of blood donations 72
5.2.1.3 Increased demand for leukopaks in clinical research 72
FIGURE 35 GROWTH IN NUMBER OF CAR-T CLINICAL TRIALS, 2009-2020 73
FIGURE 36 NUMBER OF CAR-T THERAPY CLINICAL TRIALS IN US V/S CHINA, 2022 73
5.2.2 RESTRAINTS 74
5.2.2.1 High cost of therapeutic leukapheresis and leukopaks 74
TABLE 3 COST OF LEUKOPAKS, BY TYPE 74
5.2.2.2 Stringent donor recruitment criteria 74
TABLE 4 DONOR SELECTION CRITERIA 75
TABLE 5 FREQUENCY OF BLOOD DONATIONS FROM HEALTHY DONORS 75
5.2.2.3 Dearth of skilled professionals and low adoption of therapeutic leukapheresis 76
5.2.2.4 Complications associated with therapeutic leukapheresis 76
5.2.2.5 Long procedural time for leukapheresis 76
5.2.2.6 High cost of cellular immunotherapies and lack of favorable reimbursement 77
5.2.3 OPPORTUNITIES 77
5.2.3.1 Leukapheresis for pediatric patients 77
5.2.3.2 Emerging economies with investments from academic institutes, pharma-biotech companies, and leading players 77
5.2.3.3 Gaps in current leukapheresis technologies 78
5.2.4 CHALLENGES 78
5.2.4.1 Blood transfusion safety in emerging countries 78
5.3 PORTER’S FIVE FORCES ANALYSIS 79
FIGURE 37 PORTER’S FIVE FORCES ANALYSIS (2021): LEUKAPHERESIS MARKET 79
TABLE 6 LEUKAPHERESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 79
5.3.1 THREAT FROM NEW ENTRANTS 80
5.3.2 THREAT FROM SUBSTITUTES 80
5.3.3 BARGAINING POWER OF SUPPLIERS 80
5.3.4 BARGAINING POWER OF BUYERS 81
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 81
5.4 INDUSTRY TRENDS 81
5.4.1 INCREASING NUMBER OF COLLABORATIONS AMONG PHARMA AND BIOTECH COMPANIES 81
TABLE 7 RECENT DEVELOPMENTS FOR CAR-T THERAPY 82
5.4.2 INTRODUCTION OF CUSTOMIZABLE CRYOPRESERVED LEUKOPAKS 83
5.5 TECHNOLOGY ANALYSIS 83
5.5.1 KEY TECHNOLOGIES 83
5.5.1.1 Centrifugal-based leukapheresis 83
5.5.1.2 Membrane-based leukapheresis 84
TABLE 8 MATERIALS USED FOR LEUKOCYTE FILTRATION AND SURFACE MODIFICATION TECHNIQUES APPLIED FOR ENHANCED SEPARATION 84
5.5.2 EMERGING TECHNOLOGIES 84
5.5.2.1 Adsorption-based leukapheresis 84
5.5.2.2 Microfluidic devices for leukapheresis 85
5.6 PRICING ANALYSIS (LEUKOPAKS MARKET) 85
TABLE 9 ASP OF NON-MOBILIZED LEUKOPAKS 85
TABLE 10 ASP OF MOBILIZED LEUKOPAKS 86
TABLE 11 ASP OF MOBILIZED ISOLATED CELLS 86
5.7 KEY CONFERENCES AND EVENTS IN 2022–2023 87
TABLE 12 LEUKAPHERESIS MARKET: LIST OF CONFERENCES AND EVENTS 87
5.8 REGULATORY ANALYSIS (LEUKAPHERESIS PRODUCTS MARKET) 88
5.8.1 NORTH AMERICA 88
5.8.1.1 US 88
5.8.1.2 Canada 89
5.8.2 EUROPE 89
5.8.3 ASIA PACIFIC 89
5.8.3.1 Japan 89
5.8.3.2 China 90
5.9 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 16 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 17 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
5.10 REGULATORY ANALYSIS (LEUKOPAKS MARKET) 93
5.10.1 US 93
TABLE 18 LIST OF FDA-APPROVED CAR-T THERAPEUTICS 93
5.10.2 EUROPE 94
5.10.3 JAPAN 94
5.10.4 INDIA 95
5.11 VALUE CHAIN ANALYSIS 95
FIGURE 38 VALUE CHAIN: LEUKAPHERESIS MARKET (LEUKAPHERESIS SYSTEMS) 95
5.12 SUPPLY CHAIN ANALYSIS 96
FIGURE 39 LEUKAPHERESIS MARKET: STAKEHOLDERS IN SUPPLY CHAIN 97
5.13 ECOSYSTEM ANALYSIS 97
FIGURE 40 LEUKAPHERESIS MARKET: ECOSYSTEM MAP (2021) 98
TABLE 19 LEUKAPHERESIS MARKET: ECOSYSTEM 98
5.14 PATENT ANALYSIS 99
5.14.1 PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET 99
FIGURE 41 GLOBAL PATENT PUBLICATION TRENDS IN LEUKAPHERESIS PRODUCTS MARKET, JANUARY 2018–AUGUST 2022 99
5.14.2 PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET 100
FIGURE 42 GLOBAL PATENT PUBLICATION TRENDS IN LEUKOPAKS MARKET, JANUARY 2018–AUGUST 2022 100
5.14.3 TOP APPLICANTS (COMPANIES) FOR LEUKAPHERESIS PRODUCTS PATENTS 101
FIGURE 43 TOP APPLICANT COMPANIES FOR LEUKAPHERESIS PRODUCTS PATENTS, JANUARY 2018–AUGUST 2022 101
5.14.4 TOP APPLICANTS (COMPANIES) FOR LEUKOPAKS PATENTS 101
FIGURE 44 TOP APPLICANT COMPANIES FOR LEUKOPAKS PATENTS, JANUARY 2018–AUGUST 2022 101
5.14.5 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR LEUKAPHERESIS MARKET PATENTS 102
FIGURE 45 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LEUKAPHERESIS PATENTS, JANUARY 2018–AUGUST 2022 102
FIGURE 46 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LEUKOPAKS PATENTS, JANUARY 2018–AUGUST 2022 102
5.14.6 LIST OF TOP PATENT APPLICANTS/OWNERS 103
FIGURE 47 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR LEUKAPHERESIS PRODUCTS PATENTS (JANUARY 2018–AUGUST 2022) 103
FIGURE 48 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR LEUKOPAKS PATENTS (JANUARY 2018–AUGUST 2022) 104
TABLE 20 LEUKAPHERESIS PRODUCTS MARKET: LIST OF MAJOR PATENTS (2020-2021) 104
TABLE 21 LEUKOPAKS MARKET: LIST OF MAJOR PATENTS (2019 – 2022) 106
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 107
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 107
FIGURE 49 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS 107
TABLE 22 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR LEUKAPHERESIS PRODUCTS 107
5.15.2 BUYING CRITERIA 107
FIGURE 50 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS 107
TABLE 23 KEY BUYING CRITERIA FOR LEUKAPHERESIS PRODUCTS 108
5.16 ADJACENT MARKET ANALYSIS 108
5.16.1 PLASMA FRACTIONATION MARKET 108
FIGURE 51 PLASMA FRACTIONATION MARKET OVERVIEW 108
5.16.2 APHERESIS MARKET 109
FIGURE 52 APHERESIS MARKET OVERVIEW 109
6 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE 110
6.1 INTRODUCTION 111
TABLE 24 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 25 LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
6.2 LEUKAPHERESIS DISPOSABLES 112
6.2.1 RECURRENT USAGE AND DEMAND FOR DISPOSABLES TO BOOST SEGMENT 112
TABLE 26 SOME MANUFACTURERS OF LEUKOREDUCTION FILTERS 112
TABLE 27 SOME MANUFACTURERS OF LEUKAPHERESIS COLUMNS AND CELL SEPARATORS 113
TABLE 28 LEUKAPHERESIS DISPOSABLES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 114
6.3 LEUKAPHERESIS DEVICES 114
TABLE 29 LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 30 LEUKAPHERESIS DEVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 115
6.3.1 CENTRIFUGAL DEVICES 116
6.3.1.1 Increasing installation in hospitals for therapeutic apheresis to drive market 116
TABLE 31 LIST OF SOME OF THE CENTRIFUGAL APHERESIS DEVICES AVAILABLE 116
TABLE 32 CENTRIFUGAL APHERESIS DEVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117
6.3.2 MEMBRANE SEPARATORS 117
6.3.2.1 Difficulties in separating huge volumes of plasma from milliliters of whole blood to limit market 117
TABLE 33 LIST OF SOME OF THE MEMBRANE SEPARATORS AVAILABLE 118
TABLE 34 MEMBRANE SEPARATORS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 118
7 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION 119
7.1 INTRODUCTION 120
TABLE 35 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 120
7.2 RESEARCH APPLICATIONS 120
7.2.1 INCREASED CLINICAL TRIALS TO DRIVE SEGMENT 120
TABLE 36 COMPANIES INVOLVED IN DEVELOPMENT OF FDA-APPROVED CAR T-CELL THERAPIES 120
TABLE 37 LEUKAPHERESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 121
7.3 THERAPEUTIC APPLICATIONS 121
7.3.1 RISING ADOPTION OF LEUKAPHERESIS AS A SUPPORTIVE TREATMENT IN LEUKEMIA TO FUEL MARKET 121
TABLE 38 LEUKAPHERESIS PRODUCTS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 122
8 LEUKAPHERESIS PRODUCTS MARKET, BY END USER 123
8.1 INTRODUCTION 124
TABLE 39 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 124
8.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS 124
8.2.1 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS TO DOMINATE LEUKAPHERESIS PRODUCTS MARKET 124
TABLE 40 LEUKAPHERESIS PRODUCTS MARKET FOR BLOOD COMPONENT PROVIDERS & BLOOD CENTERS, BY COUNTRY, 2020–2027 (USD MILLION) 125
8.3 ACADEMIC & RESEARCH INSTITUTES 126
8.3.1 COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO BOOST MARKET 126
TABLE 41 LEUKAPHERESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 126
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 127
8.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE SEGMENT 127
TABLE 42 PHARMA-BIOTECH COMPANIES TO DEVELOP CAR T-CELL TECHNOLOGIES 127
TABLE 43 LEUKAPHERESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 129
8.5 HOSPITALS & TRANSFUSION CENTERS 129
8.5.1 GROWING NUMBER OF HOSPITALS PERFORMING TRANSFUSIONS TO PROPEL SEGMENT 129
TABLE 44 LEUKAPHERESIS PRODUCTS MARKET FOR HOSPITALS & TRANSFUSION CENTERS, BY COUNTRY, 2020–2027 (USD MILLION) 130
9 LEUKOPAKS MARKET, BY TYPE 131
9.1 INTRODUCTION 132
TABLE 45 LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 46 LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 133
9.2 MOBILIZED LEUKOPAKS 133
9.2.1 MOBILIZED LEUKOPAKS TO DOMINATE MARKET 133
TABLE 47 TREATMENT REGIMENS FOR DEVELOPMENT OF MOBILIZED LEUKOPAKS 133
TABLE 48 MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 49 MOBILIZED LEUKOPAKS MARKET, BY REGION, 2020–2027 (UNITS) 135
9.3 NON-MOBILIZED LEUKOPAKS 136
9.3.1 LOW COST COMPARED TO MOBILIZED LEUKOPAKS TO PROPEL MARKET 136
TABLE 50 NUMBER OF CELLS IN A NON-MOBILIZED LEUKOPAK 136
TABLE 51 COMPARATIVE ANALYSIS OF MOBILIZED LEUKOPAKS AND NON-MOBILIZED LEUKOPAKS 136
TABLE 52 COMPOSITION OF MOBILIZED LEUKOPAKS AND NON-MOBILIZED LEUKOPAKS 137
TABLE 53 NON-MOBILIZED LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 137
TABLE 54 NON-MOBILIZED LEUKOPAKS MARKET, BY REGION, 2020–2027 (UNITS) 138
9.4 DISEASED LEUKOPAKS 138
9.4.1 RISING ADOPTION OF DISEASED LEUKOPAKS FOR CELL INTERACTION AND DRUG TOXICITY TO BOOST MARKET 138
TABLE 55 DISEASED LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 139
TABLE 56 DISEASED LEUKOPAKS MARKET, BY REGION, 2020–2027 (UNITS) 139
9.5 ISOLATED PBMCS 140
9.5.1 INCREASING FOCUS OF RESEARCHERS ON CELL-BASED THERAPIES TO FUEL MARKET 140
TABLE 57 ISOLATED PBMCS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 58 ISOLATED PBMCS MARKET, BY REGION, 2020–2027 (UNITS) 141
10 LEUKOPAKS MARKET, BY INDICATION 142
10.1 INTRODUCTION 143
FIGURE 53 GLOBAL NUMBER OF CLINICAL TRIALS WITH CHIMERIC ANTIGEN RECEPTOR CELLS 143
TABLE 59 LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 144
10.2 ACUTE LYMPHOCYTIC LEUKEMIA 145
10.2.1 RISING INCIDENCE OF DISEASE AND INCREASING RESEARCH IN CAR T-CELL THERAPY TO DRIVE MARKET 145
TABLE 60 LEUKOPAKS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2020–2027 (USD MILLION) 145
10.3 MULTIPLE MYELOMA 146
10.3.1 INCREASED DIAGNOSTIC RATE TO FUEL SEGMENT 146
FIGURE 54 INCIDENCES OF MULTIPLE MYELOMA IN 2020 146
TABLE 61 LEUKOPAKS MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2020–2027 (USD MILLION) 147
10.4 NON-HODGKIN’S LYMPHOMA 147
10.4.1 DEVELOPMENT OF NOVEL THERAPIES TO TREAT NON-HODGKIN’S LYMPHOMA TO BOOST SEGMENT 147
TABLE 62 LEUKOPAKS MARKET FOR NON-HODGKIN’S LYMPHOMA, BY COUNTRY, 2020–2027 (USD MILLION) 148
10.5 CHRONIC LYMPHOCYTIC LEUKEMIA 148
10.5.1 RISE IN CASES OF CHRONIC LYMPHOCYTIC LEUKEMIA TO PROPEL SEGMENT 148
TABLE 63 LEUKOPAKS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2020–2027 (USD MILLION) 149
10.6 PANCREATIC CANCER 149
10.6.1 DEVELOPMENT OF NEW DIAGNOSTIC TECHNIQUES TO IDENTIFY PANCREATIC CANCER TO DRIVE SEGMENT 149
FIGURE 55 INCIDENCES OF PANCREATIC CANCER IN 2020 150
TABLE 64 LEUKOPAKS MARKET FOR PANCREATIC CANCER, BY COUNTRY, 2020–2027 (USD MILLION) 150
10.7 HEPATOCELLULAR CARCINOMA 151
10.7.1 INCREASING INCIDENCE OF VIRAL HEPATITIS AND HEPATOCELLULAR CARCINOMA TO FUEL SEGMENT 151
TABLE 65 LEUKOPAKS MARKET FOR HEPATOCELLULAR CARCINOMA, BY COUNTRY, 2020–2027 (USD MILLION) 151
10.8 OTHER INDICATIONS 152
TABLE 66 LEUKOPAKS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 153
11 LEUKOPAKS MARKET, BY END USER 154
11.1 INTRODUCTION 155
TABLE 67 LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 155
11.2 ACADEMIC & RESEARCH INSTITUTES 155
11.2.1 INCREASING INDUSTRY−ACADEMIC PARTNERSHIPS FOR RESEARCH ON CELL-BASED CANCER THERAPIES TO DRIVE MARKET 155
TABLE 68 LEUKOPAKS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 156
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 156
11.3.1 RISING DEMAND FOR TARGET DRUG DEVELOPMENT UTILIZING LEUKOPAKS AS STARTING MATERIAL TO PROPEL MARKET 156
FIGURE 56 PERCENTAGE OF ALL GLOBAL CAR-T DRUGS IN US V/S CHINA, BY YEAR OF FIRST IDENTIFICATION/REPORT 157
TABLE 69 LEUKOPAKS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 157
11.4 CONTRACT RESEARCH ORGANIZATIONS 158
11.4.1 INCREASING SPONSORSHIP OF CLINICAL TRIALS TO FUEL SEGMENT 158
TABLE 70 LEUKOPAKS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 158
12 LEUKAPHERESIS MARKET, BY REGION 159
12.1 INTRODUCTION 160
FIGURE 57 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 160
TABLE 71 LEUKAPHERESIS PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION) 161
FIGURE 58 LEUKOPAKS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 161
TABLE 72 LEUKOPAKS MARKET, BY REGION, 2020–2027 (USD MILLION) 162
12.2 NORTH AMERICA 162
FIGURE 59 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 163
TABLE 73 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 163
TABLE 74 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 164
TABLE 75 NORTH AMERICA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 164
TABLE 76 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 164
TABLE 77 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 165
TABLE 78 NORTH AMERICA: LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 165
TABLE 79 NORTH AMERICA: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 165
TABLE 80 NORTH AMERICA: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 166
TABLE 81 NORTH AMERICA: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 166
12.2.1 US 166
12.2.1.1 Presence of leading pharmaceutical and biotechnology companies to drive market 166
FIGURE 60 US: NUMBER OF REGISTERED CAR T THERAPY CLINICAL TRIALS (2022) 167
TABLE 82 DIAGNOSIS-RELATED GROUP REIMBURSEMENT (DRG) 167
TABLE 83 US: KEY MACROINDICATORS 168
TABLE 84 US: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 85 US: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 86 US: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 169
TABLE 87 US: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 169
TABLE 88 US: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 89 US: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 170
TABLE 90 US: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
12.2.2 CANADA 170
12.2.2.1 Rising prevalence of blood cancer to stimulate market growth 170
TABLE 91 CANADA: KEY MACROINDICATORS 171
TABLE 92 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 93 CANADA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 94 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 95 CANADA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 172
TABLE 96 CANADA: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 97 CANADA: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 173
TABLE 98 CANADA: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 173
12.3 EUROPE 173
FIGURE 61 EUROPE: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 174
TABLE 99 EUROPE: NUMBER OF ONGOING CAR THERAPY CLINICAL TRIALS, BY COUNTRY, 2022 175
TABLE 100 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 175
TABLE 101 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 175
TABLE 102 EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 103 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 176
TABLE 104 EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 176
TABLE 105 EUROPE: LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 177
TABLE 106 EUROPE: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 177
TABLE 107 EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 178
TABLE 108 EUROPE: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 178
12.3.1 UK 178
12.3.1.1 Rising prevalence of target diseases to propel market 178
TABLE 109 UK: KEY MACROINDICATORS 179
TABLE 110 UK: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 111 UK: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 112 UK: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 180
TABLE 113 UK: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 180
TABLE 114 UK: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 115 UK: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 181
TABLE 116 UK: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 181
12.3.2 GERMANY 181
12.3.2.1 Increasing research on cancer immunotherapies to boost market 181
TABLE 117 GERMANY: KEY MACROINDICATORS 182
TABLE 118 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 119 GERMANY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 120 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 183
TABLE 121 GERMANY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 183
TABLE 122 GERMANY: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 123 GERMANY: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 184
TABLE 124 GERMANY: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 184
12.3.3 SPAIN 184
12.3.3.1 Rising focus on development of novel CAR T-cell therapies to fuel market 184
TABLE 125 SPAIN: KEY MACROINDICATORS 185
TABLE 126 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 185
TABLE 127 SPAIN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 185
TABLE 128 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 186
TABLE 129 SPAIN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 186
TABLE 130 SPAIN: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 131 SPAIN: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 187
TABLE 132 SPAIN: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 187
12.3.4 FRANCE 188
12.3.4.1 Developments in CAR-T cell therapy to drive market 188
TABLE 133 FRANCE: KEY MACROINDICATORS 188
TABLE 134 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 188
TABLE 135 FRANCE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 136 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 189
TABLE 137 FRANCE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 189
TABLE 138 FRANCE: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 190
TABLE 139 FRANCE: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 190
TABLE 140 FRANCE: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 191
12.3.5 ITALY 191
12.3.5.1 Increasing geriatric population, rising research on CAR-T cell therapy, and growing cases of leukemia to boost market 191
TABLE 141 ITALY: COMMERCIAL CAR T-CELL THERAPIES APPROVED BY EMA (2022) 191
TABLE 142 ITALY: KEY MACROINDICATORS 192
TABLE 143 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 144 ITALY: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 192
TABLE 145 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 193
TABLE 146 ITALY: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 193
TABLE 147 ITALY: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 148 ITALY: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 194
TABLE 149 ITALY: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 194
12.3.6 REST OF EUROPE 194
TABLE 150 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 151 REST OF EUROPE: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 152 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 196
TABLE 153 REST OF EUROPE: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 196
TABLE 154 REST OF EUROPE: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 155 REST OF EUROPE: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 197
TABLE 156 REST OF EUROPE: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 197
12.4 ASIA PACIFIC 197
FIGURE 62 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET SNAPSHOT 198
TABLE 157 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 198
TABLE 158 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 159 ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 160 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 199
TABLE 161 ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 200
TABLE 162 ASIA PACIFIC: LEUKOPAKS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 200
TABLE 163 ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 200
TABLE 164 ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 201
TABLE 165 ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 201
12.4.1 CHINA 201
12.4.1.1 China to witness highest growth during forecast period 201
FIGURE 63 CHINA: NUMBER OF CAR T-BASED CLINICAL TRIALS REGISTERED (2013–2020) 202
FIGURE 64 CHINA: NUMBER OF CAR-T THERAPY CLINICAL TRIALS, 2022 202
TABLE 166 CHINA: KEY MACROINDICATORS 203
TABLE 167 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 203
TABLE 168 CHINA: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 203
TABLE 169 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 204
TABLE 170 CHINA: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 204
TABLE 171 CHINA: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 204
TABLE 172 CHINA: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 205
TABLE 173 CHINA: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 205
12.4.2 JAPAN 205
12.4.2.1 Research activities to focus on leukopak-based cell therapies 205
TABLE 174 JAPAN: KEY MACROINDICATORS 206
TABLE 175 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 176 JAPAN: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 177 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 207
TABLE 178 JAPAN: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 207
TABLE 179 JAPAN: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 207
TABLE 180 JAPAN: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 208
TABLE 181 JAPAN: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 208
12.4.3 REST OF ASIA PACIFIC 208
TABLE 182 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 209
TABLE 183 REST OF ASIA PACIFIC: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 210
TABLE 184 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 210
TABLE 185 REST OF ASIA PACIFIC: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 210
TABLE 186 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 211
TABLE 187 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 211
TABLE 188 REST OF ASIA PACIFIC: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 212
12.5 REST OF THE WORLD 212
TABLE 189 REST OF THE WORLD: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 212
TABLE 190 REST OF THE WORLD: LEUKAPHERESIS DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 191 REST OF THE WORLD: LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 213
TABLE 192 REST OF THE WORLD: LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION) 213
TABLE 193 REST OF THE WORLD: LEUKOPAKS MARKET, BY TYPE, 2020–2027 (USD MILLION) 214
TABLE 194 REST OF THE WORLD: LEUKOPAKS MARKET, BY INDICATION, 2020–2027 (USD MILLION) 214
TABLE 195 REST OF THE WORLD: LEUKOPAKS MARKET, BY END USER, 2020–2027 (USD MILLION) 215
13 COMPETITIVE LANDSCAPE 216
13.1 INTRODUCTION 216
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 216
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKAPHERESIS PRODUCTS MARKET 217
13.2.2 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LEUKOPAKS MARKET 218
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 219
FIGURE 65 LEUKAPHERESIS MARKET: REVENUE SHARE ANALYSIS OF TOP FOUR MARKET PLAYERS 219
13.4 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKETS 220
TABLE 196 COMPANY PRODUCT FOOTPRINT 220
TABLE 197 COMPANY INDUSTRY FOOTPRINT 221
TABLE 198 COMPANY APPLICATION FOOTPRINT 222
TABLE 199 COMPANY REGION FOOTPRINT 223
13.5 LEUKAPHERESIS PRODUCTS MARKET SHARE (2021) 224
TABLE 200 LEUKAPHERESIS PRODUCTS MARKET: DEGREE OF COMPETITION 224
FIGURE 66 LEUKAPHERESIS PRODUCTS MARKET SHARE, BY KEY PLAYER (2021) 225
13.6 LEUKOPAKS MARKET SHARE (2021) 225
TABLE 201 LEUKOPAKS MARKET: DEGREE OF COMPETITION 225
FIGURE 67 LEUKOPAKS MARKET SHARE, BY KEY PLAYER (2021) 226
13.7 COMPANY EVALUATION QUADRANT (LEUKAPHERESIS PRODUCTS MARKET) 226
13.7.1 STARS 226
13.7.2 EMERGING LEADERS 227
13.7.3 PERVASIVE PLAYERS 227
13.7.4 PARTICIPANTS 227
FIGURE 68 LEUKAPHERESIS PRODUCTS MARKET: COMPANY EVALUATION QUADRANT, 2021 228
13.8 COMPETITIVE EVALUATION QUADRANT FOR START-UPS/SMES (LEUKAPHERESIS MARKET) (2021) 228
TABLE 202 LEUKAPHERESIS MARKET: DETAILED LIST OF KEY START-UPS/SMES 229
13.8.1 PROGRESSIVE COMPANIES 229
13.8.2 DYNAMIC COMPANIES 230
13.8.3 STARTING BLOCKS 230
13.8.4 RESPONSIVE COMPANIES 230
FIGURE 69 LEUKAPHERESIS MARKET: SME/START-UP COMPANY EVALUATION QUADRANT, 2021 231
13.9 COMPETITIVE EVALUATION QUADRANT (LEUKOPAKS MARKET) 231
13.9.1 STARS 232
13.9.2 EMERGING LEADERS 232
13.9.3 PERVASIVE PLAYERS 232
13.9.4 PARTICIPANTS 232
FIGURE 70 LEUKOPAKS MARKET: COMPANY EVALUATION QUADRANT (2021) 233
13.10 COMPETITIVE SITUATIONS AND TRENDS 233
TABLE 203 PRODUCT LAUNCHES AND APPROVALS (JANUARY 2019–AUGUST 2022) 233
TABLE 204 DEALS (JANUARY 2019–AUGUST 2022) 234
TABLE 205 OTHER DEVELOPMENTS (JANUARY 2019–AUGUST 2022) 235

14 COMPANY PROFILES 236
14.1 KEY PLAYERS (LEUKAPHERESIS PRODUCTS MARKET) 236
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
14.1.1 TERUMO BCT 236
TABLE 206 TERUMO CORPORATION: COMPANY OVERVIEW 236
FIGURE 71 TERUMO CORPORATION: COMPANY SNAPSHOT (2022) 237
14.1.2 FRESENIUS SE & CO. KGAA 240
TABLE 207 FRESENIUS SE & CO. KGAA: COMPANY OVERVIEW 240
FIGURE 72 FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT (2021) 241
14.1.3 HAEMONETICS CORPORATION 244
TABLE 208 HAEMONETICS CORPORATION: COMPANY OVERVIEW 244
FIGURE 73 HAEMONETICS CORPORATION: COMPANY SNAPSHOT (2022) 245
14.1.4 ASAHI KASEI CORPORATION 248
TABLE 209 ASAHI KASEI CORPORATION: COMPANY OVERVIEW 248
FIGURE 74 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2021) 249
14.1.5 MACOPHARMA SA 251
TABLE 210 MACOPHARMA SA: COMPANY OVERVIEW 251
14.1.6 MILTENYI BIOTEC 253
TABLE 211 MILTENYI BIOTEC: COMPANY OVERVIEW 253
14.2 OTHER PLAYERS (LEUKAPHERESIS PRODUCTS MARKET) 255
14.2.1 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD. 255
TABLE 212 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD.: COMPANY OVERVIEW 255
14.2.2 MEDICA SPA. 256
TABLE 213 MEDICA SPA: COMPANY OVERVIEW 256
14.2.3 PURIBLOOD MEDICAL CO. LTD. 257
TABLE 214 PURIBLOOD MEDICAL CO. LTD.: COMPANY OVERVIEW 257
14.2.4 BEIJING ZKSK TECHNOLOGY CO. LTD. 258
TABLE 215 BEIJING ZKSK TECHNOLOGY CO. LTD.: COMPANY OVERVIEW 258
14.2.5 SB-KAWASUMI LABORATORIES, INC. 259
TABLE 216 SB-KAWASUMI LABORATORIES, INC.: COMPANY OVERVIEW 259
14.2.6 NIKKISO CO., LTD. 260
TABLE 217 NIKKISO CO., LTD.: COMPANY OVERVIEW 260
FIGURE 75 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2021) 261
14.2.7 PALL CORPORATION 262
TABLE 218 PALL CORPORATION: COMPANY OVERVIEW 262
14.3 KEY PLAYERS (LEUKOPAKS MARKET) 263
14.3.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 263
TABLE 219 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY OVERVIEW 263
FIGURE 76 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021) 264
14.3.2 DISCOVERY LIFE SCIENCES, INC. 267
TABLE 220 DISCOVERY LIFE SCIENCES, INC.: COMPANY OVERVIEW 267
14.3.3 BIOIVT 270
TABLE 221 BIOIVT: COMPANY OVERVIEW 270
14.3.4 PRECISION FOR MEDICINE, INC. 273
TABLE 222 PRECISION FOR MEDICINE, INC.: COMPANY OVERVIEW 273
14.3.5 STEMEXPRESS, LLC 274
TABLE 223 STEMEXPRESS, LLC: COMPANY OVERVIEW 274
14.4 OTHER PLAYERS (LEUKOPAKS MARKET) 277
14.4.1 LONZA GROUP AG 277
TABLE 224 LONZA GROUP AG: COMPANY OVERVIEW 277
FIGURE 77 LONZA GROUP AG: COMPANY SNAPSHOT (2021) 278
14.4.2 CALTAG MEDSYSTEMS LIMITED 280
TABLE 225 CALTAG MEDSYSTEMS LIMITED: COMPANY OVERVIEW 280
14.4.3 ZENBIO, INC. 281
TABLE 226 ZENBIO, INC.: COMPANY OVERVIEW 281
14.4.4 INTELLIGENT TISSUE GROUP 282
14.4.5 TRINA BIOREACTIVES AG 282
14.4.6 ACCEGEN 282
14.4.7 FIRST CHOICE BIO LLC 283
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
15 APPENDIX 284
15.1 DISCUSSION GUIDE 284
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 291
15.3 CUSTOMIZATION OPTIONS 293
15.4 RELATED REPORTS 293
15.5 AUTHOR DETAILS 294


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com